Pfizer CEO Albert Bourla has warned that Germany’s proposed drug pricing policies could put planned pharmaceutical investments in the country at risk.
In a letter to German Chancellor Friedrich Merz, Bourla criticized the lack of predictability created by the proposed legislation, arguing that it makes long-term pharmaceutical investment planning more difficult.
Pricing Policy Is Becoming Industrial Policy
The dispute reflects a broader tension across Europe. Governments are trying to control healthcare spending, while drugmakers argue that aggressive pricing pressure can reduce incentives for innovation and manufacturing investment.
Drug pricing is no longer only a healthcare budget issue. It is becoming an industrial competitiveness issue.
Germany wants to remain a major location for pharmaceutical production, R&D and high-value life sciences investment. But if companies believe pricing rules are unpredictable, they may reconsider where to place future projects.
The warning follows similar investment pullbacks or reassessments by other pharmaceutical companies in Germany.
Europe Faces a Difficult Balance
For governments, lower medicine costs can reduce pressure on public health systems. For drugmakers, however, lower pricing visibility can weaken the commercial case for major investment.
This creates a difficult balance: Europe wants affordable medicines, but it also wants secure local production and innovation capacity.
If pricing reform is too aggressive, the risk is not only lower margins. It may also be fewer future investments.
For the pharmaceutical supply chain, Germany’s policy debate will be watched closely by companies deciding where to locate production, clinical development and advanced manufacturing.
